Nothing Special   »   [go: up one dir, main page]

SE0302305D0 - Novel Compounds - Google Patents

Novel Compounds

Info

Publication number
SE0302305D0
SE0302305D0 SE0302305A SE0302305A SE0302305D0 SE 0302305 D0 SE0302305 D0 SE 0302305D0 SE 0302305 A SE0302305 A SE 0302305A SE 0302305 A SE0302305 A SE 0302305A SE 0302305 D0 SE0302305 D0 SE 0302305D0
Authority
SE
Sweden
Prior art keywords
novel compounds
novel
compounds
Prior art date
Application number
SE0302305A
Other languages
English (en)
Inventor
Roger Bonnert
Rukhsana Rasul
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SE0301569A priority Critical patent/SE0301569D0/sv
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302305A priority patent/SE0302305D0/sv
Publication of SE0302305D0 publication Critical patent/SE0302305D0/sv
Priority to TW099109193A priority patent/TW201024261A/zh
Priority to TW093114113A priority patent/TWI328004B/zh
Priority to ARP040101792A priority patent/AR044552A1/es
Priority to EP10180348A priority patent/EP2281815B1/en
Priority to AT10180348T priority patent/ATE552243T1/de
Priority to SI200431874T priority patent/SI2281815T1/sl
Priority to AT08165755T priority patent/ATE502010T1/de
Priority to KR1020117009790A priority patent/KR20110050754A/ko
Priority to PL04734774T priority patent/PL1656346T3/pl
Priority to EP08165755A priority patent/EP2025670B1/en
Priority to ES08165755T priority patent/ES2361485T3/es
Priority to PT08165755T priority patent/PT2025670E/pt
Priority to US10/558,228 priority patent/US7687535B2/en
Priority to RU2005137403/04A priority patent/RU2361860C2/ru
Priority to MYPI20041992A priority patent/MY144483A/en
Priority to PT10180348T priority patent/PT2281815E/pt
Priority to CN2011102633202A priority patent/CN102391171A/zh
Priority to SI200431669T priority patent/SI2025670T1/sl
Priority to PL10180348T priority patent/PL2281815T3/pl
Priority to AT04734774T priority patent/ATE425965T1/de
Priority to AU2004242624A priority patent/AU2004242624B2/en
Priority to KR1020057022513A priority patent/KR101067586B1/ko
Priority to NZ543722A priority patent/NZ543722A/xx
Priority to KR1020117009788A priority patent/KR101067535B1/ko
Priority to DK04734774T priority patent/DK1656346T3/da
Priority to ES04734774T priority patent/ES2322650T3/es
Priority to CN2004800146027A priority patent/CN1795174B/zh
Priority to DK10180348.4T priority patent/DK2281815T3/da
Priority to DK08165755.3T priority patent/DK2025670T3/da
Priority to SI200431120T priority patent/SI1656346T1/sl
Priority to ES10180348T priority patent/ES2382606T3/es
Priority to JP2006532212A priority patent/JP4541361B2/ja
Priority to PT04734774T priority patent/PT1656346E/pt
Priority to MXPA05012680A priority patent/MXPA05012680A/es
Priority to BRPI0410711A priority patent/BRPI0410711B8/pt
Priority to DE602004020072T priority patent/DE602004020072D1/de
Priority to DE602004031894T priority patent/DE602004031894D1/de
Priority to EP04734774A priority patent/EP1656346B1/en
Priority to PCT/SE2004/000808 priority patent/WO2004106302A1/en
Priority to CA2526866A priority patent/CA2526866C/en
Priority to PL08165755T priority patent/PL2025670T3/pl
Priority to IL171928A priority patent/IL171928A/en
Priority to CO05118882A priority patent/CO5630030A2/es
Priority to ZA200509598A priority patent/ZA200509598B/en
Priority to IS8189A priority patent/IS2722B/is
Priority to NO20056130A priority patent/NO20056130L/no
Priority to HK06111158.9A priority patent/HK1090635A1/xx
Priority to IL194872A priority patent/IL194872A0/en
Priority to US12/397,618 priority patent/US20090163518A1/en
Priority to HR20090281T priority patent/HRP20090281T1/xx
Priority to CY20091100564T priority patent/CY1109104T1/el
Priority to HK11107570.0A priority patent/HK1149563A1/xx
Priority to HK09105852.7A priority patent/HK1126773A1/xx
Priority to JP2010082748A priority patent/JP2010155862A/ja
Priority to IS8920A priority patent/IS8920A/is
Priority to US13/047,280 priority patent/US20110263614A1/en
Priority to IL212265A priority patent/IL212265A0/en
Priority to IL212371A priority patent/IL212371A0/en
Priority to HR20110359T priority patent/HRP20110359T1/hr
Priority to CY20111100464T priority patent/CY1111469T1/el
Priority to US13/344,051 priority patent/US20120178764A1/en
Priority to HRP20120390TT priority patent/HRP20120390T1/hr
Priority to CY20121100486T priority patent/CY1112853T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE0302305A 2003-05-27 2003-08-27 Novel Compounds SE0302305D0 (sv)

Priority Applications (65)

Application Number Priority Date Filing Date Title
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds
TW099109193A TW201024261A (en) 2003-05-27 2004-05-19 Substituted indoles and preparation and use thereof
TW093114113A TWI328004B (en) 2003-05-27 2004-05-19 Substituted indoles and use thereof
ARP040101792A AR044552A1 (es) 2003-05-27 2004-05-24 Derivados del indol,composiciones farmaceuticas que los contienen y procesos para su preparacion, de utilidad para el tratamiento de trastornos respiratorios
EP10180348A EP2281815B1 (en) 2003-05-27 2004-05-25 4-(Acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid ethyl ester intermediate compound
AT10180348T ATE552243T1 (de) 2003-05-27 2004-05-25 4-(acetylamino)-3-ä(4-chlorophenyl)thioü-2-meth l-1h-indole-1-essigsäure-ethyl-ester zwischenverbindung
SI200431874T SI2281815T1 (sl) 2003-05-27 2004-05-25 Vmesna spojina etil estra 4-(acetilamino)-3-((4-klorofenil)tio)-2-metil-1H-indol-1-ocetne kisline
AT08165755T ATE502010T1 (de) 2003-05-27 2004-05-25 Verwendung von 3-phenylthio-1h-indol-1-essigsäure-derivate als modulatoren der crth2-rezeptor- aktivität
KR1020117009790A KR20110050754A (ko) 2003-05-27 2004-05-25 신규한 치환된 3-황 인돌
PL04734774T PL1656346T3 (pl) 2003-05-27 2004-05-25 1,2,3,4-Tetrapodstawiony indol do leczenia chorób dróg oddechowych
EP08165755A EP2025670B1 (en) 2003-05-27 2004-05-25 Use of 3-phenylthio-1H-indole-1-acetic acid derivatives as modulators of CRTh2 receptor activity
ES08165755T ES2361485T3 (es) 2003-05-27 2004-05-25 Uso de derivados de ácido 3-feniltio-1h-indol-acético como moduladores de la actividad del receptor crth2.
PT08165755T PT2025670E (pt) 2003-05-27 2004-05-25 Utiliza??o de derivados do ?cido 3-feniltio-1h-indole-1-ac?tico como moduladores da actividade dos receptores crth2
US10/558,228 US7687535B2 (en) 2003-05-27 2004-05-25 Substituted 3-sulfur indoles
RU2005137403/04A RU2361860C2 (ru) 2003-05-27 2004-05-25 Новые замещенные 3-сера-индолы
MYPI20041992A MY144483A (en) 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
PT10180348T PT2281815E (pt) 2003-05-27 2004-05-25 Composto intermediário de éster etílico do ácido 4-(acetilamino)-3-[(4-clorofenil)tio]-2-metil-1h-indole- 1-acético
CN2011102633202A CN102391171A (zh) 2003-05-27 2004-05-25 新型取代的3-硫吲哚
SI200431669T SI2025670T1 (sl) 2003-05-27 2004-05-25 Uporaba derivatov 3-feniltio-1H-indol-1-ocetne kisline kot modulatorjev aktivnosti CRTh2 receptorja
PL10180348T PL2281815T3 (pl) 2003-05-27 2004-05-25 Związek pośredni, ester etylowy kwasu 4-(acetyloamino)-3-[(4-chlorofenylo}tio]-2-metylo-1H-indolooctowego
AT04734774T ATE425965T1 (de) 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
AU2004242624A AU2004242624B2 (en) 2003-05-27 2004-05-25 Novel substituted 3-sulfur indoles
KR1020057022513A KR101067586B1 (ko) 2003-05-27 2004-05-25 신규한 치환된 3-황 인돌
NZ543722A NZ543722A (en) 2003-05-27 2004-05-25 Novel substituted 3-sulfur indoles
KR1020117009788A KR101067535B1 (ko) 2003-05-27 2004-05-25 신규한 치환된 3-황 인돌
DK04734774T DK1656346T3 (da) 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
ES04734774T ES2322650T3 (es) 2003-05-27 2004-05-25 Indol 1,2,3,4-tetrasustituido para el tratamiento de enfermedades respiratorias.
CN2004800146027A CN1795174B (zh) 2003-05-27 2004-05-25 取代的3-硫吲哚
DK10180348.4T DK2281815T3 (da) 2003-05-27 2004-05-25 4-(Acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-1H-indole-1-acetic acid ethyl ester intermediate compound
DK08165755.3T DK2025670T3 (da) 2003-05-27 2004-05-25 Anvendelse af 3-phenylthio-1H-indol-1-eddikesyre-derivater som modulatorer af CRTh2-receptor aktivitet
SI200431120T SI1656346T1 (sl) 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
ES10180348T ES2382606T3 (es) 2003-05-27 2004-05-25 Compuesto intermedio éster etílico del ácido 4-(acetilamino)-3-[(4-clorofenil)tio]-2-metil-1H-indol-acético
JP2006532212A JP4541361B2 (ja) 2003-05-27 2004-05-25 新規３位硫黄置換インドール
PT04734774T PT1656346E (pt) 2003-05-27 2004-05-25 Indole 1,2,3,4-tetrassubstituído para o tratamento de doenças respiratórias
MXPA05012680A MXPA05012680A (es) 2003-05-27 2004-05-25 Indoles novedosos de 3-azufre sustituidos.
BRPI0410711A BRPI0410711B8 (pt) 2003-05-27 2004-05-25 ácido 4-(acetilamina)-3-[(4-clorofenil)tio]-2-metil-1h-indol-1-acético
DE602004020072T DE602004020072D1 (de) 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE602004031894T DE602004031894D1 (de) 2003-05-27 2004-05-25 Verwendung von 3-Phenylthio-1H-indol-1-essigsäure-Derivate als Modulatoren der CRTh2-Rezeptor-Aktivität
EP04734774A EP1656346B1 (en) 2003-05-27 2004-05-25 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
PCT/SE2004/000808 WO2004106302A1 (en) 2003-05-27 2004-05-25 Novel substituted 3-sulfur indoles
CA2526866A CA2526866C (en) 2003-05-27 2004-05-25 Substituted 3-sulfur indoles for treating a disease mediated by crth2
PL08165755T PL2025670T3 (pl) 2003-05-27 2004-05-25 Zastosowanie pochodnych kwasu 3-fenylotio-1H-indolo-1-octowego jako modulatorów aktywności receptora CRTh2
IL171928A IL171928A (en) 2003-05-27 2005-11-14 Compounds of 4 - (acetylamino) - 3 - [(4 - chlorophenyl) thio] - 2 - methyl - 1H - indole - 1 - acetic acid, salts and their solvates, and their uses in the preparation of medicine
CO05118882A CO5630030A2 (es) 2003-05-27 2005-11-23 Acido 4-(acetilamino)-3-{(4-clorofenil)tio}-2-metil-1h-indol-1-acetico y composicion farmaceutica que lo contiene
ZA200509598A ZA200509598B (en) 2003-05-27 2005-11-28 Novel substituted 3-sulfur indoles
IS8189A IS2722B (is) 2003-05-27 2005-12-20 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
NO20056130A NO20056130L (no) 2003-05-27 2005-12-22 Nye substituerte 3-svovelindoler
HK06111158.9A HK1090635A1 (en) 2003-05-27 2006-10-11 Substituted 3-sulfur indoles
IL194872A IL194872A0 (en) 2003-05-27 2008-10-23 Novel substituted 3-sulfur indoles
US12/397,618 US20090163518A1 (en) 2003-05-27 2009-03-04 Novel Compounds
HR20090281T HRP20090281T1 (en) 2003-05-27 2009-05-15 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
CY20091100564T CY1109104T1 (el) 2003-05-27 2009-05-28 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
HK11107570.0A HK1149563A1 (sv) 2003-05-27 2009-06-30
HK09105852.7A HK1126773A1 (sv) 2003-05-27 2009-06-30
JP2010082748A JP2010155862A (ja) 2003-05-27 2010-03-31 新規３位硫黄置換インドール
IS8920A IS8920A (is) 2003-05-27 2010-08-09 3-(Fenýl eða kínólyl)þíó- 1H-idnól-1-ediksýru afleður sem mótarar á virkni CRTh2 vitaka.
US13/047,280 US20110263614A1 (en) 2003-05-27 2011-03-14 Novel compounds
IL212265A IL212265A0 (en) 2003-05-27 2011-04-11 Novel compounds
IL212371A IL212371A0 (en) 2003-05-27 2011-04-14 Novel compounds
HR20110359T HRP20110359T1 (hr) 2003-05-27 2011-05-16 Upotreba derivata 3-feniltio-1h-indol-1-octene kiseline kao modulatora crth2 receptorske aktivnosti
CY20111100464T CY1111469T1 (el) 2003-05-27 2011-05-16 ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ 3-ΦΑΙΝΥΛΘΕΙΟ-1Η-ΙΝΔΟΛΗ-1-ΟΞΙΚΟΥ ΟΞΕΟΣ ΩΣ ΡΥΘΜΙΣΤΕΣ ΤΗΣ ΔΡΑΣΗΣ ΤΟΥ ΥΠΟΔΟΧΕΑ CRTh2
US13/344,051 US20120178764A1 (en) 2003-05-27 2012-01-05 Novel Compounds
HRP20120390TT HRP20120390T1 (hr) 2003-05-27 2012-05-10 Intermedijarni spoj etil estera 4-(acetilamino)-3-[(4-klorofenil)tio]-2-metil-1h-indol-1-octene kiseline
CY20121100486T CY1112853T1 (el) 2003-05-27 2012-05-29 Ενδιαμεση ενωση 4-(ακετυλαμινο)-3-[(4-χλωροφαινυλ)θειο]-2-μεθυλ-1η-ινδολη-1-οξικο οξυ αιθυλεστερα

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds

Publications (1)

Publication Number Publication Date
SE0302305D0 true SE0302305D0 (sv) 2003-08-27

Family

ID=33492578

Family Applications (2)

Application Number Title Priority Date Filing Date
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds

Country Status (31)

Country Link
US (4) US7687535B2 (sv)
EP (3) EP2281815B1 (sv)
JP (2) JP4541361B2 (sv)
KR (3) KR101067586B1 (sv)
CN (2) CN1795174B (sv)
AR (1) AR044552A1 (sv)
AT (3) ATE552243T1 (sv)
AU (1) AU2004242624B2 (sv)
BR (1) BRPI0410711B8 (sv)
CA (1) CA2526866C (sv)
CO (1) CO5630030A2 (sv)
CY (3) CY1109104T1 (sv)
DE (2) DE602004020072D1 (sv)
DK (3) DK1656346T3 (sv)
ES (3) ES2361485T3 (sv)
HK (3) HK1090635A1 (sv)
HR (3) HRP20090281T1 (sv)
IL (4) IL171928A (sv)
IS (2) IS2722B (sv)
MX (1) MXPA05012680A (sv)
MY (1) MY144483A (sv)
NO (1) NO20056130L (sv)
NZ (1) NZ543722A (sv)
PL (3) PL1656346T3 (sv)
PT (3) PT1656346E (sv)
RU (1) RU2361860C2 (sv)
SE (2) SE0301569D0 (sv)
SI (3) SI2025670T1 (sv)
TW (2) TW201024261A (sv)
WO (1) WO2004106302A1 (sv)
ZA (1) ZA200509598B (sv)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
SI1725553T1 (sl) 2004-03-11 2008-08-31 Actelion Pharmaceuticals Ltd Derivati tetrahidropiridoindola
NZ556657A (en) 2004-12-27 2010-10-29 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
AU2006237365B2 (en) 2005-04-21 2012-09-20 Merck Serono Sa 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2
AU2006251138C1 (en) 2005-05-24 2013-08-29 Merck Serono Sa Tricyclic spiro derivatives as CRTH2 modulators
EP1916245B1 (en) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indole derivative having pgd2 receptor antagonist activity
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP2407453A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. PGD2 receptor antagonist
JP4990285B2 (ja) * 2005-09-30 2012-08-01 プルマジェン セラピューティクス（アズマ）リミテッド キノリンおよびその治療的使用
US7741360B2 (en) * 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
WO2007149312A2 (en) 2006-06-16 2007-12-27 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
NZ574375A (en) * 2006-07-22 2011-06-30 Oxagen Ltd 2-(5-fluoro-2-methyI-3-(2-(phenylsulfonyl)benzyl)-1H-indol-1-yl) acetic acid derivatives having CRTH2 antagonist activity
ATE530523T1 (de) 2006-08-07 2011-11-15 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
AU2008266853A1 (en) * 2007-06-21 2008-12-24 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
BRPI0812597A2 (pt) * 2007-06-21 2015-02-18 Actimis Pharmaceuticals Inc Sal, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação do sal
DK2327693T3 (da) 2007-12-14 2012-08-13 Pulmagen Therapeutics Asthma Ltd Indoler og terapeutisk anvendelse deraf
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2010039982A1 (en) * 2008-10-01 2010-04-08 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CA2751260A1 (en) 2009-02-12 2010-08-19 Stefano Crosignani Phenoxy acetic acid derivatives
JP5675800B2 (ja) * 2009-07-06 2015-02-25 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ ４−（アセチルアミノ））−３−［（４−クロロ−フェニル）チオ］−２−メチル−１ｈ−インドール−１−酢酸の製造のための中間体および方法
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US9032565B2 (en) 2009-12-16 2015-05-19 Kohler Co. Touchless faucet assembly and method of operation
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
WO2011117798A1 (en) 2010-03-22 2011-09-29 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
MX338516B (es) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
AU2012351342A1 (en) 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
EP2827952B1 (en) 2012-03-21 2021-07-07 The Trustees Of The University Of Pennsylvania Composition for stimulating hair growth
US9550750B2 (en) * 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
HUE039380T2 (hu) 2013-03-15 2018-12-28 Plexxikon Inc Heterociklusos vegyületek és alkalmazásaik
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN105473578A (zh) * 2013-05-24 2016-04-06 加州生物医学研究所 用于治疗抗药性和持续性结核病的化合物
MA39750B1 (fr) 2014-03-17 2018-12-31 Idorsia Pharmaceuticals Ltd Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
TW201620909A (zh) 2014-03-18 2016-06-16 艾克泰聯製藥有限公司 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2016128565A1 (en) 2015-02-13 2016-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
ES2947824T3 (es) 2015-07-30 2023-08-21 Univ Pennsylvania Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
EP3350179B1 (en) 2015-09-15 2021-01-13 Idorsia Pharmaceuticals Ltd Crystalline forms
JP2020536917A (ja) 2017-10-13 2020-12-17 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節するための化合物の固体形態

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
HUT74614A (en) 1993-02-24 1997-01-28 Merck & Co Inc Nindol derivates suitable for treatment of infection by hiv and pharmaceutical compositions containing them
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU9025898A (en) 1997-08-21 1999-03-08 American Home Products Corporation Solid phase synthesis of 2,3-disubstituted indole compounds
DE69814012T2 (de) 1997-12-19 2004-04-01 Eli Lilly And Co., Indianapolis Hypoglykàmische imidazoline derivate
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
WO2001032621A1 (fr) * 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif
IL150388A0 (en) 1999-12-24 2002-12-01 Aventis Pharma Ltd Azaindoles
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
JP4595182B2 (ja) * 2000-09-07 2010-12-08 ソニー株式会社 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体
US6933316B2 (en) * 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
ATE340792T1 (de) 2002-02-01 2006-10-15 Hoffmann La Roche Substituierte indole als alpha-1 agonisten
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP2423190A1 (en) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
RU2006109108A (ru) * 2003-10-14 2007-11-20 Оксаген Лимитед (GB) Соединения, обладающие активностью антагонистов crth2 рецепторов
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
US7741360B2 (en) * 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
CA2654026A1 (en) 2006-06-08 2007-12-13 Neurokey A/S Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
JP5237938B2 (ja) 2006-06-28 2013-07-17 サノフイ 新規なｃｘｃｒ２阻害剤

Also Published As

Publication number Publication date
CN1795174A (zh) 2006-06-28
PT2025670E (pt) 2011-05-24
TW200510301A (en) 2005-03-16
KR101067535B1 (ko) 2011-09-27
US7687535B2 (en) 2010-03-30
IL212265A0 (en) 2011-06-30
ES2382606T3 (es) 2012-06-11
AU2004242624A1 (en) 2004-12-09
CA2526866A1 (en) 2004-12-09
DK2281815T3 (da) 2012-06-18
AU2004242624B2 (en) 2008-03-13
ATE502010T1 (de) 2011-04-15
PT1656346E (pt) 2009-05-20
HK1126773A1 (sv) 2009-09-11
BRPI0410711B8 (pt) 2021-05-25
CN1795174B (zh) 2011-09-28
ES2361485T3 (es) 2011-06-17
MY144483A (en) 2011-09-30
PT2281815E (pt) 2012-05-24
KR20110050754A (ko) 2011-05-16
IL194872A0 (en) 2011-08-01
DE602004031894D1 (de) 2011-04-28
IS8920A (is) 2010-08-09
HK1090635A1 (en) 2006-12-29
US20080249110A1 (en) 2008-10-09
SI2025670T1 (sl) 2011-06-30
DK2025670T3 (da) 2011-06-06
KR20110051297A (ko) 2011-05-17
AR044552A1 (es) 2005-09-21
CO5630030A2 (es) 2006-04-28
EP2025670B1 (en) 2011-03-16
CN102391171A (zh) 2012-03-28
EP1656346B1 (en) 2009-03-18
MXPA05012680A (es) 2006-02-08
ATE552243T1 (de) 2012-04-15
KR20060015303A (ko) 2006-02-16
RU2005137403A (ru) 2006-05-27
TW201024261A (en) 2010-07-01
EP2025670A1 (en) 2009-02-18
SI1656346T1 (sl) 2009-08-31
DK1656346T3 (da) 2009-06-15
ES2322650T3 (es) 2009-06-24
IS2722B (is) 2011-03-15
RU2361860C2 (ru) 2009-07-20
CA2526866C (en) 2012-10-16
PL2281815T3 (pl) 2012-08-31
SE0301569D0 (sv) 2003-05-27
IS8189A (is) 2005-12-20
HRP20110359T1 (hr) 2011-06-30
DE602004020072D1 (de) 2009-04-30
KR101067586B1 (ko) 2011-09-27
JP2010155862A (ja) 2010-07-15
CY1109104T1 (el) 2014-07-02
TWI328004B (en) 2010-08-01
US20090163518A1 (en) 2009-06-25
CY1112853T1 (el) 2016-02-10
IL171928A (en) 2011-06-30
HRP20090281T1 (en) 2009-06-30
PL2025670T3 (pl) 2011-07-29
BRPI0410711B1 (pt) 2018-09-25
ATE425965T1 (de) 2009-04-15
US20120178764A1 (en) 2012-07-12
US20110263614A1 (en) 2011-10-27
HRP20120390T1 (hr) 2012-06-30
PL1656346T3 (pl) 2009-07-31
NZ543722A (en) 2007-05-31
HK1149563A1 (sv) 2011-10-07
JP4541361B2 (ja) 2010-09-08
BRPI0410711A (pt) 2006-06-13
IL212371A0 (en) 2011-06-30
IL171928A0 (en) 2006-04-10
SI2281815T1 (sl) 2012-06-29
NO20056130L (no) 2006-02-27
JP2007501269A (ja) 2007-01-25
ZA200509598B (en) 2006-12-27
EP2281815B1 (en) 2012-04-04
EP2281815A1 (en) 2011-02-09
CY1111469T1 (el) 2015-08-05
EP1656346A1 (en) 2006-05-17
WO2004106302A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
SE0301569D0 (sv) Novel compounds
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
IS8108A (is) Ný efnasambönd
IS8228A (is) Ný asetídínefnasambönd
ECSP066436A (es) Compuestos heterociclicos fusionados
ATE368042T1 (de) Cephemverbindungen
IS8089A (is) Efnasambönd
IS7381A (is) Efnasambönd
IS8292A (is) Ný efnasambönd
IS7414A (is) Oxó-azabísýklísk efnasambönd
AT502792A5 (de) Düsenanpressvorrichtung
NO20045659L (no) Forbindelser
DK1633719T3 (da) Substituerede spirobenzazepiner
DE502004009935D1 (de) Substituierte dihydrochinazoline ii
NO20031736D0 (no) Forbindelser
SE0303452D0 (sv) New compounds
SE0203348D0 (sv) Novel compounds
SE0302667D0 (sv) Novel Compounds
SE0300388D0 (sv) Novel compounds
SE0300118D0 (sv) Novel Compounds
AT6592U3 (de) Frontgrubber
NO20030117D0 (no) Forbindelser
NO20035294D0 (no) Forbindelser
NO20033173D0 (no) Forbindelser
SE0303182D0 (sv) New compounds